News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.


Posted on: 12/31/2016

. Acta Neurol Scand. 2016 Dec 26. doi: 10.1111/ane.12719. [Epub ahead of print]
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Zwirner K1, Paulsen F1,2, Schittenhelm J3,2, Borchers C4,5, 2, Skardelly M6,2, Zips D1,2,7, Eckert F1,2,7.
 
Author information:
1Department of Radiation Oncology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
2Neuro-Oncology Center, Comprehensive Cancer Center Tuebingen, Tuebingen, Germany.
3Department of Neuropathology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
4Department of Neurology, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
5Department of Neurology, Sanderbusch Hospital, Sande, Germany.
6Department of Neurosurgery, University Hospital Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
7German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) partner site Tuebingen, Tuebingen, Germany.
 
Abstract
OBJECTIVES:
 
In progressive glioblastoma, salvage treatment remains unstandardized, response is highly variable, and detailed analysis of individual approaches is mandatory. Re-irradiation is an established option in the therapy of progressive glioblastoma. Thus, we analysed outcome and prognostic parameters of patients with re-irradiated glioblastoma treated at our institution since 1998.
MATERIALS AND METHODS:
 
In a total of 51 patients, clinical and treatment parameters were collected and analysed retrospectively. Re-irradiation protocols included radiosurgery, hypofractionated radiotherapy or normofractionated radiotherapy. Outcome was analysed regarding prognostic factors in this highly selected cohort.
RESULTS:
 
Median overall survival after primary diagnosis was 28.8 months. Patients re-irradiated with single-dose stereotactic radiosurgery or hypofractionated regimes showed a superior overall survival after primary diagnosis compared to normofractionated treatment. Positive prognostic factors included a smaller gross tumour volume and younger age. A methylated MGMT promoter approached statistical significance as a positive factor regarding overall survival after re-irradiation. Further well-known prognostic factors as extension of the initial resection and the concomitance of temozolomide with the initial radiation treatment only appeared relevant in a subgroup of four long-term survivors.
CONCLUSIONS:
 
The favourable results regarding overall survival are probably due to patient selection for re-irradiation. If technically feasible, stereotactic radiosurgery or hypofractionated regimes should be preferred. In this highly selected re-irradiation cohort, only some of the well-known prognostic factors of the primary tumour setting were found to influence overall survival significantly. In contrast, also some patients presenting with unfavourable predictive parameters showed an encouraging course of disease and thus should not be excluded from re-irradiation.

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites